Chidamide is a histone deacetylase inhibitor which increases Histone H3 acetylation levels in LoVo and HT29 colon cancer cells at low concentrations (4 µM). Chidamide affects the activation of oncogenic signaling kinases by dose-dependently reducing phosphorylated Akt, mTOR, p70S6K, Raf and Erk 1/2 protein expression in colon cancer cells. Chidamide also dose-dependently upregulates p21 protein expression, down-regulates CDK4, and induces cell cycle arrest at the G0/G1 phase.

This product has been cited 1 time.